• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Canterbury Conference on OCT with Emphasis on Broadband Optical Sources >Subretinal Hyper-Reflective Material Seen on Optical Coherence Tomography as a Biomarker for Disease Monitoring in Age-Related Macular Degeneration
【24h】

Subretinal Hyper-Reflective Material Seen on Optical Coherence Tomography as a Biomarker for Disease Monitoring in Age-Related Macular Degeneration

机译：在光学相干断层扫描中看到的尺度超反射材料作为疾病监测的生物标志物在年龄相关性黄斑变性中

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Subretinal hyper-reflective material (SHRM) seen on optical coherence tomography (OCT) is thought to be a collection of fibrous tissues and vascular networks that are identified in age-related macular degeneration (ARMD). We have carried out a retrospective analysis of 91 OCT scans of neovascular ARMD subtypes including classic and occult choroidal neovascularization (CNV) and retinal angiomatous proliferation (RAP). All three subtypes received ranibizumab, an anti-vascular endothelial growth factor (Anti-VEGF) intravitreal injections on an as-needed basis following the loading doses. Volumes of SHRM were calculated using caliper measurements of maximal height and length of SHRM seen on OCT. The ellipsoid formula derived from tumour models was used to calculate the volume. It was found that occult CNV and RAP have larger SHRM volumes than those of classic CNV. SHRM volumes reduced overall following loading doses of Anti-VEGF injections at 4 months in all three subtypes. However, a rebound increase in volume was noticed in both occult CNV and RAP cohort at 12 months despite the initial, steeper reductions in the subtypes. These findings were consistent with the data seen in volume measurement using Topcon's automated segmentation algorithm in a smaller cohort of patients. We propose that SHRM should be used as a potential biomarker to quantify both disease progression and prognosis of neovascular ARMD alongside other conventional methods.
机译：在光学相干断层扫描（OCT）上观察到的假体超反射材料（SHRM）被认为是在年龄相关的黄斑变性（ARMD）中鉴定的纤维组织和血管网络的集合。我们对新血管臂亚型91八个扫描进行了回顾性分析，包括经典和隐匿的脉络膜新生血管（CNV）和视网膜血管性增殖（RAP）。所有三种亚型都接受了Ranibizumab，抗血管内皮生长因子（抗VEGF）在装载剂量后根据需要的基础注射。使用OCT看到的最大高度和SHRM的最大高度和长度的CALIPER测量来计算SHRM的量。源自肿瘤模型的椭圆条功率用于计算体积。发现隐匿性CNV和RAP具有比经典CNV的体积更大。在所有三个亚型中，在4个月加载抗VEGF注射剂后，SHRM体积总体减少。然而，尽管亚型初始，陡峭的减少，但在12个月内，在潜在的CNV和RAP队列中均注意到体积增加。这些发现与在较小的患者队列中使用Topcon的自动分割算法在体积测量中看到的数据一致。我们提出了ShRM应用作潜在的生物标志物，以量化与其他常规方法的疾病进展和预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号